These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30370830)

  • 21. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
    Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Chaipung B; Worrajittanon D; Leethochawalit M; Chiamwongpaet S; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Holtz TH; Samandari T; Choopanya K;
    Lancet HIV; 2017 Feb; 4(2):e59-e66. PubMed ID: 27866873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sharing of Investigational Drug Among Participants in the Voice Trial.
    Moodley J; Naidoo S; Moodley J; Ramjee G
    AIDS Behav; 2016 Nov; 20(11):2709-2714. PubMed ID: 27146827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emtricitabine/tenofovir disoproxil fumarate.
    Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions.
    Minnis AM; van der Straten A; Salee P; Hendrix CW
    AIDS Behav; 2016 Jul; 20(7):1541-8. PubMed ID: 25969178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding women's motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence.
    Katz AWK; Mensch BS; Woeber K; Musara P; Etima J; van der Straten A
    BMC Womens Health; 2019 Jan; 19(1):18. PubMed ID: 30683103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Innovative approaches to cohort retention in a community-based HIV/STI prevention trial for socially marginalized Peruvian young adults.
    Villacorta V; Kegeles S; Galea J; Konda KA; Cuba JP; Palacios CF; Coates TJ;
    Clin Trials; 2007; 4(1):32-41. PubMed ID: 17327244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
    Trang TP; Dong BJ; Kojima N; Klausner JD
    Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
    Friend DR; Kiser PF
    Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention.
    Haire B; Kaldor J; Jordens CF
    Am J Bioeth; 2012; 12(6):21-30. PubMed ID: 22650457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
    Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
    PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
    Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-exposure chemoprophylaxis of HIV infection: quo vadis?
    Clercq ED
    Biochem Pharmacol; 2012 Mar; 83(5):567-73. PubMed ID: 22067069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MOVING FORWARD WITH PrEP. THE BASICS OF PrEP.
    Highleyman L
    Posit Aware; 2015; 27(5):2-3. PubMed ID: 26714333
    [No Abstract]   [Full Text] [Related]  

  • 39. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
    JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
    Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
    HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.